FDA 483 - Cipla Ltd. - January 20, 2020

An FDA inspection of Cipla Limited, an API manufacturer in Bangalore, India, from January 20-24, 2020, revealed significant deficiencies in their production and equipment systems. Observations included inadequate process monitoring, insufficient process validation protocols for impurity testing, incomplete batch records, and a lack of proper operational qualification for equipment. These issues indicate a failure to ensure consistent product quality and adherence to manufacturing standards.